Bayer, PHRI and C-SPIN to conduct Phase III trial of rivaroxaban to treat ESUS patients
The randomized double-blind, event-driven superiority trial is designed to examine the benefits of the once-daily, oral Factor Xa Inhibitor, rivaroxaban in these patients. Around 7,000 patients will be